Skip to content
Screener

Insulet PODD Q1 2025 earnings

Reported May 8, 2025 · After market close

Revenue$569.0MBeat by $25.7M
EPS$1.02Beat by $0.23
Revenue estimate$543.3M
EPS estimate$0.79

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$833.3M
EPS estimate$1.59

Financials

Q1 2025

Income statement

See full
Revenue$569.0M+28.8%
Gross profit$409.1M+33.3%
Operating income$88.8M+56.1%
Net income$35.4M-31.3%
EPS (diluted)$0.50-31.5%

Balance sheet

See full
Cash & equivalents$1.3B+70.8%
Total debt$1.8B+20.7%
Total equity$1.3B+68.3%
Total assets$3.5B+34.0%

Cash flow

See full
Operating cash flow$63.8M-27.2%
CapEx$12.3M-44.3%
Free cash flow$51.5M-21.4%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$18.44B+54.0%
Enterprise value$18.94B+49.2%
P/E45.9×-5.3×
P/S8.4×+1.7×

Profitability

See full
Gross margin70.4%+1.5pp
Operating margin15.5%+1.5pp
Net margin18.3%+5.2pp
FCF margin13.2%+5.1pp

Returns & leverage

See full
Return on equity37.9%+1.7pp
Debt / equity1.3×-0.5×
Current ratio4.5×+0.7×

Segments

By product

See full
International$152.3M+32.1%
Drug Delivery$14.9M+71.3%

By geography

See full
U.S.$416.6M—

FAQ

When did Insulet report Q1 2025 earnings?
Insulet (PODD) reported Q1 2025 earnings on May 8, 2025 after market close.
What were Insulet's Q1 2025 revenue and EPS?
Insulet reported revenue of $569.0M and eps of $1.02 for Q1 2025.
Did Insulet beat estimates in Q1 2025?
Revenue beat the consensus estimate of $543.3M by $25.7M. EPS beat the consensus estimate of $0.79 by $0.23.
How did Insulet's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 28.8% from $441.7M a year earlier and eps grew 39.7% from $0.73.
Where can I find Insulet's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001145197-25-000021) and the 10-Q periodic report (0001145197-25-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.